ANZCTR search results

Cognitive changes are common in prostate cancer survivors after starting hormonal treatments. This study aims to investigate the feasibility and effectiveness of an online group cognitive rehabilitation program for these survivors. Who is it for? You may be eligible for the cognitive online group intervention if you are male, aged 18 years or over, and are currently receiving hormone therapy for prostate cancer. Study details This study will be conducted in two parts. Participants who choose to enrol in the first part will be presented with an outline of the proposed cognitive rehabilitation program. Participants in part 1 will be asked to discuss the proposed program in an online focus group of up to 6 participants (and 2 research team members) . Participants will be asked to spend no more than 1 hour reading through program material to familiarise themselves with the content and then attend a 2-hour online focus group. Feedback provided by the participants in part 1 will be used to refine the proposed cognitive rehabilitation program. In the second part, participants who choose to enrol will be given access to the final online cognitive rehabilitation program. The program will be run weekly over a 4 week period. Topics to be covered in the program include how to manage fatigue and difficulties with memory, attention and other cognitive abilities. There will be pre- and post-program assessments as well as questionnaires to compare prior, throughout and after the program. It is hoped this research will determine whether a new online cognitive rehabilitation program has a positive impact on the cognitive function of prostate cancer survivors who are undergoing hormonal treatments. If this study shows promise, the rehabilitation program may be expanded so that a larger number of prostate cancer survivors may take part.

The perinatal period, encompassing pregnancy and the first year postpartum, is a time of immense change where women are faced with new challenges, stress, and high emotions (Chlebowski, 2013; Newman et al., 2007). Previous coping strategies may prove inadequate when faced with sleep deprivation, a crying infant, physical pain, role transformation, and relationship stress (Geerling et al., 2019; Sved Williams & Apter, 2017; Wilson & Donachie, 2018). Women with personality vulnerability may become emotionally unstable (Sved Williams et al., 2018; Yelland et al., 2015), and existing symptoms of borderline personality disorder (BPD) may be exacerbated (Dunn et al., 2020). The National Health and Medical Research Council (2012) guidelines recommend that women with BPD who are pregnant, have infants or young children “should be provided with interventions designed to support parenting skills and attachment relationships”. As dysregulation (Apter at al., 2017) and neurobiological disturbances (Newman et al., 2011) can occur in infants of mothers with BPD by three months of age, early intervention is imperative. We will evaluate the impact of the provision of psychoeducation material in pregnant women with BPD/BPD traits compared to general information about parenting and mental health. It is hypothesised that emotional regulation, obstetric/birth outcomes, postnatal maternal behaviours will be less compromised for women who have completed psychoeducation compared to women who have completed general information about parenting and mental health.

The proposed clinical trial will evaluate the bioavailability of Satipharm CBD capsules compared to a CBD oil at a dose of 100mg. The trial will also determine if there is bioequivalence between the Swiss manufactured Satipharm CBD capsules and Australian manufactured CBD capsules. 12 healthy male participants will receive one single oral dose of 100 mg cannabidiol (1mL of the reference drug or two tablets of the test drug) after an overnight fast in each of the 3 periods according to a sequence determined by randomisation. In each study period, participants will take different products (either one dose of the 2 Test Drugs or one dose of Reference Drug) with a minimum 13 day wash-out between each study period. The study hypothesis is that the Australian manufactured CBD capsules will show an equivalent bioavailability at the specified time points to that of the Swiss manufactured CBC capsules.

Psychological distress is widespread among university students in Australia, and rapid changes to higher education brought on by the pandemic have exacerbated this problem. There is a need for university-wide mental health prevention and early intervention programs that harness existing resources within the university setting. The Sharper Minds package is a mental health package that includes a website, a weekly progress tracker and a range of short group interventions that target behaviours related to students’ mental health (i.e., physical activity, diet, sleep, music listening for study, mood regulation, and social connection). This open trial of Sharper Minds examined engagement, retention, and effectiveness of the package in undergraduate students at the University of Queensland. We predict that students who use the weekly progress tracker and complete a short course will report better mental health and academic outcomes at the end of semester compared to students who only use one component or who don't use any package components.

The XII-01 Study is a prospective, non-randomised, multi-centre technical feasibility study that is designed to evaluate initial safety and feasibility of the investigational device. This clinical investigation is the first critical step utilizing the investigational device in a series of planned studies. The main objective of this study is temporary placement of the investigational device to confirm its ability to achieve nerve stimulation. Researchers hypothesize that this system will achieve nerve stimulation representative of stimulation that is used to treat patients with OSA.

Over the last few years, evidence has emerged that Dapagliflozin, a blood sugar lowering drug that can be administered as a tablet, does not just return blood sugar levels toward normal with minimal or no side effects but also protects the kidney form injury. This drug has also been shown to slow the progression of heart and kidney related complications of diabetes and heart failure patients. This makes treatment with Dapagliflozin potentially desirable in patients at risk of acute kidney injury who are admitted to the intensive care unit. However, the effect of Dapagliflozin in such patients, although logical, has not yet been studied. For this reason, we are planning to perform a clinical research project, known as a randomised controlled trial. We aim to evaluate whether giving oral Dapagliflozin (10mg daily for up to 28-days while in ICU) compared to placebo (a dummy tablet) in ICU patients at risk of acute kidney injury (AKI) decreases the severity and risk of injury and maintains blood sugar levels while decreasing the use of insulin. We plan to study 40 patients at high risk of developing AKI. If our findings demonstrate safety and potential benefit, they will allow this treatment to be studied in larger groups and, perhaps become a new effective treatment for these patients.

The project will evaluate education and facilitation to build the capacity of general practices to identify and appropriately treat patients with chronic conditions, frailty, pre-frailty, or early dementia, and to be supported in primary care to live well. Primary care has an important role to play to support healthy ageing for early intervention of chronic disease. However, implementation of healthy ageing interventions into routine primary care has been limited, The program involves early identification, and provision of evidence-based support to improve quality of life and promote Healthy Ageing for people between the age of 40-70 years. This project will include a mixed methods approach, guided by the application of the Consolidated Framework for Implementation Research (CFIR) and RE-AIM frameworks.

This study will investigate the effect of adding CT imaging to guide the standard endobrachial ultrasound (EBUS) method of collecting lung tissue for the diagnosis of potential lung cancers. Who is it for? You may be eligible for this study if you are an adult ages 18 years or older, you live in South Australia and you have been referred to the Royal Adelaide Hospital lung cancer clinic with a pulmonary lesion (suspected lung cancer) that requires a biopsy to be taken. Only participants who are eligible to undergo a radial EBUS procedure will be invited to participate in this study. Study details All participants who choose to enrol in this study will undergo a general anaesthetic in order to have the EBUS procedure. The EBUS procedure will be undertaken per the standard method, which involves introducing a flexible camera (bronchoscope) into the participants airway via their throat. An ultrasound probe will also be used to identify the lesion to be biopsied. As part of this study, additional CT imaging will also take place prior to the lesion being biopsied. This imaging will not involve any additional injections and is anticipated to add 15 minutes to the overall procedure and anaesthesia time. It is hoped this research will determine whether adding CT imaging during the lung biopsy procedure is able to improve the ability of surgeons and physicians to collect the tissue sample accurately and with fewer attempts. If this imaging is found to have a positive impact on the accuracy and duration of the biopsy procedure it may be trialled in a larger number of potential lung cancer patients in a future clinical trial.

An eHealth solution – Music Attuned Technology for Care via eHealth (MATCH) – was developed to support family and professional carers of people living with dementia to use music intentionally to support care. The MATCH mobile application was developed as an extension of an in-person music intervention training program (HOMESIDE) which involved a qualified music therapist offering one-on-one training to carers in the intentional use of music. To create scalable solutions for the growing number of people living with dementia in the community, we developed the MATCH App. The homecare version of the app was tested in 2022 for people living with dementia and being cared for by family caregivers.(ACTRN12622000193774). The new version of the MATCH App is developed for Residential Care (RAC) settings to attend to several care staff and residents simultaneously. This proof-of-concept study aims to test the MATCH RAC version. I will a) test and evaluate whether the MATCH Music Training Program content is learned by carers of people living with dementia, b) the MATCH App is feasible, acceptable, and useful to apply the strategies in the care of people living with dementia; c) examine the user experience and evaluate the design features of the mobile app.

Ingrown toenails are a common presentation to any podiatry setting (Borges et al., 2017; Khunger & Kandhari, 2012). Although the true prevalence of this condition is difficult to determine, it has been reported to occur in approximately 2.5-5% of the population (Vural et al., 2018). Treatment often involves surgical excision using a local anaesthetic digital ring block (most commonly using plain lidocaine) (Eekhof et al., 2012). These injections can be a source of pain and anxiety for patients. If patients have a severe needle phobia, they are often referred to have the procedure conducted in theatre under a general anaesthetic. Hundreds of South Australians are currently on the public elective surgery waiting list for this procedure, the majority of which are triaged as a Category 3 with a recommended waiting time of within 365 days (Australian Institute of Health and Welfare, 2023). These patients risk prolonged infection, pain, and deterioration of their condition, which can place unnecessary emotional and economic burden on the patient, and the health care system (Oudhoff et al., 2007). SA Health, as the provider of public health in South Australia, have recently approved the use of inhaled methoxyflurane by Podiatrists who meet prescribing requirements. The use of methoxyflurane for podiatric surgical procedures can provide a lower risk and more timely alternative for patients with a needle phobia to receive care without the need for general anaesthesia (Jephcott et al., 2018). In this situation, methoxyflurane can be used as an analgesic prior to and during the local anaesthetic injections enabling many more patients to have their procedure performed in outpatient (OPD) clinics. In addition to improving patient outcomes, this could reduce elective surgical waiting lists and the demand for surgical services, reducing the overall cost that these procedures would otherwise have on the health care system. Hypothesis: Is self-administered, inhaled methoxyflurane (Penthrox®) effective in reducing pain during local anaesthetic administration in a Podiatry Outpatient setting?